Search

Search Constraints

You searched for: Author/Creator Cicin, I

Search Results

1. 127POutcomes based on albumin‐bilirubin (ALBI) grade in the phase III CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC). (24th November 2019)

2. 1401PThe efficacy and safety of crizotinib in patients with ROS1 positive advanced stage NSCLC: The real-world experience from Turkey. (23rd October 2018)

3. 325PPertuzumab, trastuzumab and taxane combination for visceral organ metastatic patients: Real life practice results. (23rd October 2018)

4. 703PAssessment of disease burden in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC). (23rd October 2018)

5. LBA62Health-related quality of life (HRQoL) for pembrolizumab or placebo plus carboplatin and paclitaxel or nab-paclitaxel in patients with metastatic squamous NSCLC: Data from KEYNOTE-407. (23rd October 2018)

7. O-011Assessment of tumor response, AFP response, and time to progression in the phase 3 CELESTIAL trial of cabozantinib versus placebo in advanced hepatocellular carcinoma (HCC). (20th June 2018)

8. O-022Outcomes based on Albumin‐Bilirubin (ALBI) grade in the phase 3 CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC). (2nd July 2019)